- Conditions
- Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
- Interventions
- Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires
- Drug · Behavioral · Other
- Lead sponsor
- Brian Anderson, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 152
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Otolaryngeal Cancer
- Interventions
- Ketamine, Placebo, Electroencephalogram (EEG)
- Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Depression, Anhedonia
- Interventions
- Continuous theta burst stimulation (cTBS), Positive Affect Training, Ketamine Injectable Solution
- Device · Behavioral · Drug
- Lead sponsor
- Erika Forbes
- Other
- Eligibility
- 15 Years to 25 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- PTSD, Posttraumatic Stress Disorder
- Interventions
- Ketamine, Placebo/Saline
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 3
- States / cities
- West Haven, Connecticut • Minneapolis, Minnesota • San Antonio, Texas
- Conditions
- Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
- Interventions
- Ketamine, Normal Saline
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Opioid Use Disorder, Suicidal Ideation
- Interventions
- Ketamine, Saline Solution
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Traumatic Pain
- Interventions
- Ketamine Hydrochloride, Placebo-Comparator
- Drug
- Lead sponsor
- Jason McMullan
- Other
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Depression
- Interventions
- Lithium, Ketamine, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hip Fractures, Anesthesia, Spinal, Anesthesia, General, Neuromuscular Blockade
- Interventions
- Rocuronium, Sugammadex, Normal saline
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Multiple Sclerosis
- Interventions
- ketamine
- Drug
- Lead sponsor
- Alta Bates Summit Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Berkeley, California
- Conditions
- Suicidal Ideation, Depression, Alcohol Abuse
- Interventions
- Intranasal ketamine, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy
- Interventions
- Ketamine
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 13 participants
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Pain, Nausea
- Interventions
- ropivacaine, Lidocaine/Ketamine, placebo
- Drug · Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Mayfield Heights, Ohio
- Conditions
- Depression
- Interventions
- Placebos, Ketamine, Nitroprusside
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sedation
- Interventions
- Dexmedetomidine load, Ketamine load, Midazolam load, Fentanyl load, Dexmedetomidine maintenance, Ketamine maintenance, Midazolam demand, Fentanyl demand, Benadryl demand
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Depression, Suicide
- Interventions
- 0.2 mg/kg ketamine, placebo
- Drug · Other
- Lead sponsor
- United States Naval Medical Center, San Diego
- Federal
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Hospital Inpatient Trauma Injury, Pain Management
- Interventions
- Ketamine, Placebo
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Excitatory Amino Acid Agents, Physiological Effects of Drugs, Depressive Disorder, Major, Depressive Disorder, Depression, Mental Disorders, Mood Disorders, Behavioral Symptoms
- Interventions
- (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Major Depressive Disorder
- Interventions
- Esketamine, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 18
- States / cities
- Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more
- Conditions
- Schizophrenia
- Interventions
- PF-04958242, Ketamine, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 21 Years to 45 Years · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • West Haven, Connecticut
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- Esketamine 56 mg, Esketamine 84 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 44 more
- Conditions
- Major Depressive Disorder
- Interventions
- Ketamine, Scopolamine
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts